Advertisement

Topics

Xeljanz Doesn't Improve Radiographic Progression In Psoriatic Arthritis. Does It Matter?

17:42 EDT 1 Aug 2017 | SCRIP

Pfizer's JAK inhibitor met its co-primary efficacy endpoints, but US FDA still wants discussion of lack of impact on radiographic...

      

Related Stories

 

Original Article: Xeljanz Doesn't Improve Radiographic Progression In Psoriatic Arthritis. Does It Matter?

NEXT ARTICLE

More From BioPortfolio on "Xeljanz Doesn't Improve Radiographic Progression In Psoriatic Arthritis. Does It Matter?"

Quick Search
Advertisement
 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...